University of California San Francisco
Give to UCSF
Breast cancer was the second most commonly diagnosed cancer in women, after skin cancer – accounting for 31% of all new female cancer diagnoses in 2022. Yet, determining who is most at risk of breast
Laura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
Researchers have found that people who developed breast, ovary, skin and uterine cancers have significantly higher levels of endocrine-disrupting chemicals in their bodies.
Engineered immune cells. Supercharged scans. Drug implants. Gene manipulators. Blood biopsies. Read how these breakthroughs are transforming cancer care.
Laws in many states require notifying women if they have dense breasts, a risk factor for breast cancer. But density shouldn’t be the only factor in determining whether supplemental screening is
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
Leading cancer researchers from UCSF will present at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 14-19, 2023, in Orlando.
A new digital tool helps to calculate breast cancer risk for those who may develop advanced cancer that goes undiagnosed despite regular screenings.
Sick leave coverage expansion were associated with higher rates of mammography screening and colorectal screening, potentially leading to better health outcomes.
The WISDOM 2.0 study aims to transform breast cancer screening by using a personalized approach and will expand to women as young as 30.
UCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Helen Diller Family Cancer Research BuildingExperts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
Researchers at UCSF and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease.
Researchers at UCSF have gained insight into how cancer cells proliferate despite a myriad of stresses.
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs.
A new, $9 million grant from the National Cancer Institute to increase ethnic diversity will help the study work toward a goal of enrolling 100,000 or more women overall.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.